[1]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269-1273.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(12):1269-1273.
点击复制

肝癌TACE还是HAIC？()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年12
页码:
1269-1273
栏目:
专论
出版日期:
2024-12-25

文章信息/Info

Title:
Treatment of hepatocellular carcinoma：TACE or HAIC？
作者:
杜楠; 王英; 李文涛
Author(s):
DU Nan; WANG Ying; LI Wentao.
Department of Interventional Radiology，Affiliated Cancer Hospital of Fudan University；Department of Oncology，Shanghai Medical College of Fudan University，Shanghai 200032，China
关键词:
【关键词】肝细胞癌; 经导管动脉化疗栓塞术; 肝动脉灌注化疗; 分子靶向药物治疗
文献标志码:
A
摘要:
【摘要】经导管动脉化疗栓塞术（TACE）是目前中晚期不可切除肝癌的常用治疗方法。近年来，国内奥沙利铂+氟尿嘧啶+亚叶酸钙（FOLFOX）方案的肝动脉灌注化疗（hepatic artery infusion chemotherapy，HAIC）已用于治疗中晚期肝癌。HAIC联合应用分子靶向药物和（或）免疫检查点抑制剂，取得了令人鼓舞的成果。该文介绍了TACE和HAIC的理论基础、发展史及研究进展，分析比较二者的疗效和不良反应，以期为中晚期肝癌患者选择治疗时机及治疗方案提供参考。

参考文献/References:

［1］郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2024,46：221-231.
［2］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66：115-132.
［3］秦叔逵，邱文生，熊建萍，等.真实世界中经动脉化疗栓塞治疗肝细胞癌患者临床应用调研分析［J］.临床肿瘤学杂志，2024，29：6-13.
［4］Idee JM，Guiu B.Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma：a review［J］.Crit Rev Oncol Hematol，2013，88：530-549.
［5］Namur J，Citron SJ，Sellers MT，et al.Embolization of hepatocellular carcinoma with drug-eluting beads：doxorubicin tissue concentration and distribution in patient liver explants［J］.J Hepatol，2011，55：1332-1338.
［6］Xie DY，Zhu K，Ren ZG，et al.A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma：updates and insights［J］.Hepatobiliary Surg Nutr，2023，12：216-228.
［7］Yamada R，Sato M，Kawabata M，et al.Hepatic artery embolization in 120 patients with unresectable hepatoma［J］.Radiology，1983，148：397-401.
［8］Wáng YXJ，De Baere T，Idee JM，et al.Transcatheter embolization therapy in liver cancer：an update of clinical evidences［J］.Chin J Cancer Res，2015，27：96-121.
［9］Lewis AL，Taylor R，Hall B，et al.Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization［J］.J Vasc Interv Radiol，2006，17：1335-1343.
［10］Melchiorre F，Patella F，Pescatori L，et al.DEB-TACE：a standard review［J］.Future Oncol，2018，14：2969-2984.
［11］Launchbury AP，Habboubi N.Epirubicin and doxorubicin：a comparison of their characteristics，therapeutic activity and toxicity［J］.Cancer Treat Rev，1993，19：197-228.
［12］张雯，周永杰，颜志平.再论精细TACE［J］.介入放射学杂志，2021，30：971-975.
［13］中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞（TACE）治疗临床实践指南（2023年版）［J］.中华医学杂志，2023，103：2674-2694.
［14］European Association For The Study Of The Liver，European Organisation For Research And Treatment Of Cancer.EASL-EORTC clinical practice guidelines：management of hepatocellular carcinoma［J］.J Hepatol，2012，56：908-943.
［15］国家卫生计生委.国家卫生计生委发布《原发性肝癌诊疗规范（2017年版）》［J］.中华医学信息导报，2017，32：7.
［16］国家卫生健康委办公厅.原发性肝癌诊疗指南（2022年版）［J］.浙江实用医学，2022，27：528-536.
［17］Benson AB，D′Angelica MI，Abbott DE，et al.Hepatobiliary cancers，version 2.2021，NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw，2021，19：541-565.
［18］Anderson SD，Holley HC，Berland LL，et al.Causes of jaundice during hepatic artery infusion chemotherapy［J］.Radiology，1986，161：439-442.
［19］Reed ML，Vaitkevicius VK，Al-Sarraf M，et al.The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies：ten-year results of 124 patients in a prospective protocol［J］.Cancer，1981，47：402-409.
［20］Shepherd FA，Evans WK，Blackstein ME，et al.Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma［J］.J Clin Oncol，1987，5：635-640.
［21］Zhou XD，Tang ZY，Yu YQ，et al.Hepatic artery ligation and infusion chemotherapy for unresectable primary liver cancer［J］.Chin Med J （Engl），1991，104：846-850.
［22］Yamasaki T，Kimura T，Kurokawa F，et al.Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy［J］.J Gastroenterol，2005，40：70-78.
［23］Ganeshan A，Upponi S，Hon LQ，et al.Hepatic arterial infusion of chemotherapy：the role of diagnostic and interventional radiology［J］.Ann Oncol，2008，19：847-851.
［24］Qin S，Bai Y，Lim HY，et al.Randomized，multicenter，open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia［J］.J Clin Oncol，2013，31：3501-3508.
［25］Lencioni R，de Baere T，Soulen MC，et al.Lipiodol transarterial chemoembolization for hepatocellular carcinoma：a systematic review of efficacy and safety data［J］.Hepatology，2016，64：106-116.
［26］Kudo M，Han KH，Ye SL，et al.A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma：Asia-Pacific primary liver cancer expert consensus statements［J］.Liver Cancer，2020，9：245-260.
［27］Kudo M，Ueshima K，Ikeda M，et al.Final results of TACTICS：a randomized，prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma［J］.Liver Cancer，2022，11：354-367.
［28］Peng Z，Fan W，Zhu B，et al.Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma：a phase Ⅲ，randomized clinical trial （LAUNCH）［J］.J Clin Oncol，2023，41：117-127.
［29］Yau T，Park JW，Finn RS，et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma （CheckMate 459）：a randomised，multicentre，open-label，phase 3 trial［J］.Lancet Oncol，2022，23：77-90.
［30］Qin S，Chen Z，Fang W，et al.Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma：a randomized，double-blind，phase Ⅲ trial［J］.J Clin Oncol，2023，41：1434-1443.
［31］Cheng AL，Qin S，Ikeda M，et al.Updated efficacy and safety data from IMbrave150：Atezolizumab plus bevacizumab vs.sorafenib for unresectable hepatocellular carcinoma［J］.J Hepatol，2022，76：862-873.
［32］Xu J，Shen J，Gu S，et al.Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma （RESCUE）：a nonrandomized，open-label，phase Ⅱ trial［J］.Clin Cancer Res，2021，27：1003-1011.
［33］Wu JY，Yin ZY，Bai YN，et al.Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma：a multicenter retrospective study［J］.J Hepatocell Carcinoma，2021，8：1233-1240.
［34］Zhu HD，Li HL，Huang MS，et al.Transarterial chemoe-mbolization with PD-（L）1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma （CHANCE001）［J］.Signal Transduct Target Ther，2023，8：58.
［35］Jin ZC，Zhong BY，Chen JJ，et al.Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC （CHANCE2211）：a propensity score matching study［J］.Eur Radiol，2023，33：8669-8681.
［36］Lyu N，Kong Y，Mu L，et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs.sorafenib for advanced hepatocellular carcinoma［J］.J Hepatol，2018，69：60-69.
［37］Zheng K，Zhu X，Fu S，et al.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis：a randomized trial［J］.Radiology，2022，303：455-464.
［38］He MK，Liang RB，Zhao Y，et al.Lenvatinib，toripalimab，plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma［J］.Ther Adv Med Oncol，2021，13：17588359211002720..
［39］Zhang TQ，Geng ZJ，Zuo MX，et al.Camrelizumab （a PD-1 inhibitor） plus apatinib （an VEGFR-2 inhibitor） and hepatic artery infusion chemotherapy for hepatocellular carcinoma in barcelona clinic liver cancer stage C （TRIPLET）：a phase Ⅱ study［J］.Signal Transduct Target Ther，2023，8：413.
［40］Chen S，Zhang K，Liu W，et al.Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma：a phase Ⅱ，single-arm，prospective study［J］.Eur J Cancer，2020，134：90-98.
［41］He MK，Le Y，Li QJ，et al.使用mFOLFOX进行肝动脉灌注化疗与肝动脉化疗栓塞术治疗不可切除的巨块型肝细胞癌：一项前瞻性非随机研究［J］.癌症，2018，37：251-259.
［42］Li QJ，He MK，Chen HW，et al.Hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma：a randomized phase Ⅲ trial［J］.J Clin Oncol，2022，40：150-160.
［43］赵东旭，张磊，姜小庆，等.HAIC是老技术还是新方法——理性看待肝动脉灌注化疗［J］.介入放射学杂志，2022，31：2-8.
［44］Li B，Qiu J，Zheng Y，et al.Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma［J］.Ann Surg Open，2021，2：e057.
［45］Huang Z，Wu Z，Zhang L，et al.The safety and efficacy of TACE combined with HAIC，PD-1 inhibitors，and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma：a retrospective study［J］.Front Oncol，2024，14：1298122.
［46］中国抗癌协会肝癌专业委员会.肝动脉灌注化疗治疗肝细胞癌中国专家共识（2021版）［J］.中华消化外科杂志，2021，20：754-759.
［47］中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南（2024年版）［J］.协和医学杂志，2024，15：532-558.

相似文献/References:

[1]黄渊全,贾中芝,冯耀良,等.CT灌注成像在肝癌TACE术后疗效评价中的应用价值[J].介入放射学杂志,2009,(06):437.
　HUANG Yuan-quan,JIA Zhong-zhi,FENG Yao-liang,et al.Clinical application of CT perfusion imaging in estimating the efficacy of transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2009,(12):437.
[2]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(12):543.
[3]陈成,沈艳峰,董云,等.阿帕替尼联合TACE治疗原发性肝癌有效性和安全性meta分析 [J].介入放射学杂志,2020,29(03):251.
　CHEN Cheng,SHEN Yanfeng,DONG Yun,et al.Apatinib combined with TACE for primary liver cancer: a meta-analysis of its effectiveness and safety[J].journal interventional radiology,2020,29(12):251.
[4]于清泳,赵 辉.结直肠癌肝转移患者TACE治疗后含表皮生长因子的纤维蛋白样细胞外基质2水平及意义 [J].介入放射学杂志,2021,30(10):1035.
　YU Qingyong,ZHAO Hui..The level and significance of EGF containing fibulin-like extracellular matrix protein 2 in patients with liver metastases from colorectal cancer after TACE treatment[J].journal interventional radiology,2021,30(12):1035.
[5]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(12):55.
[6]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(12):36.
[7]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(12):90.
[8]秦焕蓉,程芝梅,吴祥锴,等.经导管动脉化疗栓塞和微波消融治疗VX2肝癌诱导低氧诱导因子-1α调节糖酵解与微血管密度相关性分析研究[J].介入放射学杂志,2024,33(04):390.
　QIN Huanrong,CHENG Zhimei,WU Xiangkai,et al.Correlation between HIF-1α regulation of glycolysis and microvessel density induced by transcatheter arterial chemoembolization and microwave ablation in experimental rabbits with VX2 hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):390.
[9]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):921.
[10]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):968.
[11]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):1039.
[12]张赛锋,王道仁,邵国良.小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析[J].介入放射学杂志,2024,33(12):1373.
　ZHANG Saifeng,WANG Daoren,SHAO Guoliang..Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis[J].journal interventional radiology,2024,33(12):1373.

备注/Memo

备注/Memo:
（收稿日期：2024-07-23）
（本文编辑：新宇）
更新日期/Last Update: 2024-12-18